KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.

Tao Huang, Zhimin Fan, Yongsheng Wang, Xi Yan, Hongjian Yang, Shu Wang, Da Pang, Huiping Li, Haibo Wang, Cuizhi Geng, Liang Huang, Yaqing Sun, Bei Wang, Guofang Sun, Asna Siddiqui, Eleonora Restuccia, Zhimin Shao

Int J Clin Oncol 31(7) 1189-1200

PMID42098463
PMCIDPMC13303565
DOI10.1007/s10147-025-02935-7
发表日期2026-05-07
入排依据:The study is a randomized, phase III oncology trial with a drug intervention and original results. However, it does not include a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is pharmacokinetic (serum trough concentration), and secondary endpoints include pathological complete response and safety.
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram。
摘要

摘要

BACKGROUND: Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (Ctrough), and similar total pathological complete response (tpCR) rates and safety, to intravenous pertuzumab plus trastuzumab (P + H IV) in HER2-positive early breast cancer (eBC). In the FDChina study (NCT04024462), we assessed neoadjuvant-adjuvant PH FDC SC vs. P + H IV in Chinese patients with HER2-positive eBC. METHODS: Patients received four doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2), then four docetaxel (75-100 mg/m2) cycles, every 3 weeks. Patients were randomized 1:1 to PH FDC SC (loading: 1200 mg pertuzumab/600 mg trastuzumab; maintenance: 600 mg/600 mg) or P + H IV (loading: 840 mg/8 mg/kg; maintenance: 420 mg/6 mg/kg) alongside docetaxel before surgery. Patients then continued HER2-targeted therapy for 14 cycles. Co-primary non-inferiority endpoints: cycle 7 pertuzumab and trastuzumab Ctrough. Secondary endpoints: tpCR, long-term efficacy, safety. RESULTS: The lower bounds of the 90% confidence intervals of pertuzumab and trastuzumab cycle 7 geometric mean ratios (0.99 and 1.44, respectively) exceeded the pre-specified non-inferiority margin (0.8). tpCR rates were 55.6% for PH FDC SC vs. 56.4% for P + H IV. Grade ≥ 3 adverse events occurred in 72% vs. 69% of patients. CONCLUSION: The study met the co-primary endpoints of non-inferiority of cycle 7 serum Ctrough for pertuzumab and trastuzumab for PH FDC SC vs. P + H IV. tpCR rates and safety were comparable between arms. PH FDC SC may be a viable treatment option for Chinese patients with HER2-positive eBC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Study design. AC doxorubicin plus cyclophosphamide, BC breast cancer, C trough trough concentration, DRFI distant recurrence-free interval, EFS event-free survival, ER estrogen receptor, H trastuzumab, HR hormone receptor, IDFS invasive disease-free survival, IV intravenous, N + node-positive, OS overall survival, P pertuzumab, PgR progesterone receptor, PH FDC SC fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, q3w every 3 weeks, tpCR total pathological complete response, wks weeks, yrs years
非 KM Figure
Fig. 2Fig. 2 Patient disposition. AE adverse event, C trough trough concentration, H trastuzumab, ITT intention to treat, IV intravenous, P pertuzumab, PH FDC SC fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, PK pharmacokinetic. a Reasons for exclusion: five patients had missing C trough pre-dose cycle 8 PK samples, three patients had their C trough sample collected with ≥ 2 days deviation from the planned-on Day 21, two patients had a dose amount that deviated from the planned dose by > 20%, one patient had a dose delay of > 7 days, and one patient’s samples needed to be checked to see whether the pre-dose and post-dose samples were switched. b Reasons for exclusion: five patients had missing C trough pre-dose cycle 8 PK samples, three patients had their C trough sample collected with ≥ 2 days deviation from the planned-on Day 21, three patients had a dose amount that deviated from the planned dose by > 20%, and one patient had a dose delay of > 7 days. c Reasons for exclusion: four patients had missing C trough pre-dose cycle 8 PK samples and six patients had their C trough sample collected with ≥ 2 days deviation from the planned-on Day 21. d Reasons for exclusion: four patients had missing C trough pre-dose cycle 8 PK samples and six patients had their C trough sample collected with ≥ 2 days deviation from the planned-on Day 21. e Includes patients who withdrew due to the COVID-19 pandemic. f Reasons include patient noncompliance, death, and progressive disease (after completing neoadjuvant treatment but prior to surgery)
非 KM Figure